← Back to Clinical Trials
Recruiting NCT06913998

NCT06913998 The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06913998
Status Recruiting
Phase —
Sponsor National Taiwan University Hospital
Condition Inflammatory Bowel Diseases
Study Type OBSERVATIONAL
Enrollment 65 participants
Start Date 2023-12-27
Primary Completion 2026-01

Trial Parameters

Condition Inflammatory Bowel Diseases
Sponsor National Taiwan University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 65
Sex ALL
Min Age 1 Year
Max Age 25 Years
Start Date 2023-12-27
Completion 2026-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The study will include participants who were diagnosed with inflammatory disease and followed up at National Taiwan University Children's Hospital. The investigators will check the NUDT15 gene test, if the participant agrees to do an additional blood test. The result of the gene test will be analyzed and compared with other clinical data.

Eligibility Criteria

Inclusion Criteria: * Participants who are diagnosed with inflammatory bowel disease. Exclusion Criteria: * Participants who refused to have blood test for NUDT15 gene evaluation.

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE INFLAMMATORY BOWEL DISEASES TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology